登录新浪财经APP 搜索【信披】查看更多考评等级 点击查看公告原文>> 责任编辑：小浪快报 投资者关系活动关键信息活动类别：业绩说明会时间：2025年9月3日（周三）15:00 - 16:30地点：通过 全景网"投资者关系互动平台"（https://ir.p5w.net）采用网络远程方式召开参与单位名称及人员姓名：线 上参与公司2025年半年度网上业绩说明会的投资者上市公司接待人员姓名：公司董事长兼首席执行官薛 永江；公司副总裁、董事会秘书、财务总监胡大伟；独立董事刘娅；保荐代表人石坡 业绩说明会精彩要点上半年业绩大增原因：2025年上半年恩威医药实现净利润3834.42万元，同比增加 113.80%。主要源于河南信心药业部分重点产品复产上市带来市场增量；线上销售渠道业务，尤其非药 类产品销售保持高速增长；摊销费用同比大幅降低。同时，公司所处医药制造行业中长期向好，短期存 在一定波动。下半年工作重点：一是扎实开展日常经营，组织生产满足市场需求，开拓线下线上市场确 保全年目标达成；二是全力推进河南信心药业重点产品发展计划，年内完成约20个重点产品复产上市； 三是稳步推进川药募投项目建设，确保合规高质量完成今年任 ...

中国经济周刊-经济网讯 两市午后走势分化，沪指、深证成指继续走低，创指午后走强。截至今日 收盘，上证综指报3813.56点，跌幅1.16%，成交额10122.96亿元；深证成指报12472.00点，跌幅0.65%， 成交额13517.90亿元；创业板指报2899.37点，涨幅0.95%，成交额6526.56亿元。 盘面上，芯片概念股活跃，博杰股份、长飞光纤等多股涨停；医药板块走势稍强，百花医药、人福 医药等涨停；另外，BC电池概念、电气设备等板块涨幅居前；国防军工、多元金融、证券等多数板块 下跌。 编辑：何颖曦 ...

| | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 √业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | 线上参与公司 年半年度网上业绩说明会的投资者 2025 | | 人员姓名 | | | 时间 | 年 月 日（周三）15:00~16:30 2025 9 3 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | | 1、公司董事长兼首席执行官薛永江 | | 上市公司接待人 | 2、公司副总裁、董事会秘书、财务总监胡大伟 | | 员姓名 | 3、独立董事刘娅 | | | 4、保荐代表人石坡 | | | 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | | 1、上半年，公司经营业绩实现快速增长，尤其是归母 | | | 净利润增速超过 100%。请问董事长，上半年公司业绩大幅 | | 投资者关系活动 | 增长的主 ...

Core Viewpoint - Lianhua Technology (002250) has experienced significant profit growth in the first half of 2025, driven by cost reduction, operational efficiency improvements, and favorable exchange rate gains [1] Group 1: Profit Growth Reasons - The company's profit in the first half of 2025 increased significantly compared to the same period last year due to continuous cost reduction and efficiency enhancement [1] - The utilization rate of the plant protection business improved, and the product structure was adjusted, leading to an increase in gross margin [1] - The pharmaceutical business saw notable growth due to concentrated shipments and substantial exchange rate gains [1] Group 2: Pharmaceutical Business Developments - The pharmaceutical business growth is attributed to a focus on major clients, with partnerships established with several leading global pharmaceutical companies [1] - The company is actively expanding its client base, particularly targeting strategic and high-viscosity clients [1] - Collaborations have been established with a number of high-quality domestic and international clients [1] Group 3: Plant Protection Business Factors - The company follows a customer-centric strategy, providing a stable supply chain, comprehensive product delivery capabilities, and high-quality services [1] - The UK subsidiary improved its capacity utilization and operational performance in the first half of the year [1] - The UK subsidiary also achieved significant exchange rate gains, enhancing overall performance [1] Group 4: New Energy Project Progress - The company has achieved stable supply and gradual production increases for electrolyte products [1] - New energy products, including main salt products and cathode materials, have achieved stable commercial delivery [1] - The company anticipates that revenue from the new energy business will exceed expectations in 2025 [1] Group 5: Solid-State Battery Strategy - The company is actively monitoring industry trends and developing products in response to customer needs [1] - There is a focus on optimizing services and technology to reduce costs and promote innovation [1] Group 6: Competitive Landscape in India - Indian companies have entered the CDMO field, primarily focusing on generic drug supply chains, with unclear competitiveness in patented drugs [1] - While India has advantages in compliance and labor costs, China possesses a more comprehensive supply chain and a mature waste treatment system [1] - The company believes that maintaining its competitive edge will allow it to sustain market share and profitability despite emerging competitors [1]

联化科技股份有限公司投资者关系活动记录表 公司新能源业务跟随客户需求，积极关注行业前沿产品开 发情况，结合公司自身能力，做好产品规划，优化服务及技术， 降低成本，促进创新，以期未来。 3、今年公司英国子公司的生产经营情况有很大改善，主要原 因有哪些？ 公司一直坚持紧跟客户战略，为客户提供更稳定的供应 链、更完整的产品体系交付能力及更优质的服务。公司积极开 拓客户，引进新的产品，英国子公司上半年度产能利用率提升， 经营情况得到一定的改善。同时，上半年度英国子公司实现了 较大的汇兑收益，亦进一步提升了其上半年度的收益表现。 4、目前，公司新能源项目的进展如何？公司对这一业务的展 望情况如何？ 经过前期积累，目前公司已实现电解液产品的稳定供应， 并逐步提升产量。在此基础上，公司新能源系列产品包括电解 质主盐产品、正极材料等均实现稳定的商业化交付。2025 年， 公司新能源业务营业收入有望实现突破。公司一直坚信新能源 行业是发展长远，市场规模较大的行业，这一行业与公司的价 值观和自身能力有极高的契合度，公司相信凭借公司自身的能 力积累能够最终在这一行业中获得竞争优势。 5、公司新能源业务是否有固态电池的布局？如何看待 ...

人民财讯9月3日电，今日，三大指数走势分化，沪指、深证成指走弱，创业板指维持震荡。截至收盘， 沪指跌1.16%，深证成指跌0.65%，创业板指涨0.95%。盘面上，芯片概念股活跃，博杰股份、长飞光纤 等多股涨停；医药板块走势稍强，百花医药（维权）、人福医药（维权）等涨停；另外，BC电池概 念、电气设备等板块涨幅居前；国防军工、多元金融、证券等多数板块下跌。全市场总成交额约2.4万 亿元。 MACD金叉信号形成，这些股涨势不错！ 责任编辑：刘万里 SF014 ...

延伸阅读： 2025年1至6月份，东北制药的营业收入构成为：医药制造业占比52.0%，医药商业占比46.18%，其他行 业占比1.82%。 长久物流:公司财务总监靳婷辞职 安孚科技:聘任刘剑波为公司财务总监 广誉远:聘任任岩为公司财务总监 每经AI快讯，东北制药（SZ 000597）9月1日晚间发布公告称，周雅娜女士因个人身体原因申请辞去公 司财务总监职务。 截至发稿，东北制药市值为82亿元。 ...

Core Viewpoint - WuXi AppTec (02268) has entered into a placement agreement to issue up to 22.277 million shares at a price of HKD 58.85 per share, potentially raising approximately HKD 1.311 billion in total proceeds [1] Group 1: Placement Details - The placement is conditional and will be conducted through a placement agent to at least six independent third-party investors [1] - If fully subscribed, the net proceeds from the placement are expected to be around HKD 1.301 billion [1] Group 2: Use of Proceeds - Approximately 90% of the proceeds will be allocated to expanding the company's service capabilities and production capacity, including clinical and commercial production of antibody-drug conjugates and active pharmaceutical ingredients [1] - The remaining 10% will be used for working capital needs and general corporate purposes [1]

关于控股股东、实际控制人及一致行动人 协议转让公司部分股份进展暨签署补充协议的公告 公司控股股东、实际控制人及其一致行动人和受让方保证向本公司提供的信 息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 营产生重大影响。 证券代码：002082 证券简称：万邦德 公告编号：2025-054 万邦德医药控股集团股份有限公司 甲方二：庄惠 甲方三：温岭惠邦投资咨询有限公司 甲方四：温岭富邦投资咨询有限公司 结算有限责任公司深圳分公司办理股份协议转让过户手续，是否能够最终完成尚 存在不确定性，敬请广大投资者注意投资风险。 一、协议转让概况 控股股东万邦德集团有限公司（以下简称"万邦德集团"）、实际控制人赵守明 先生、庄惠女士、一致行动人温岭惠邦投资咨询有限公司（以下简称"温岭惠邦"）、 温岭富邦投资咨询有限公司（以下简称"温岭富邦"）（上述各方合并简称"出 让方"）与温岭市万龙医药科技合伙企业（有限合伙）(以下简称"万龙医药" "受让方"）签署了《股份转让协议》（以下简称"《原协议》"），拟通过协 ...

Group 1 - Daoshi Technology's subsidiary Hong Kong Jiana invested $30 million in Brain Family Inc. to acquire minority shareholder rights through Pre-B round preferred shares [1] - Brain Family Inc. is a leading company in brain-computer interface technology with unique technical barriers and commercialization capabilities [1] - Daoshi Technology aims to enhance its "AI + new materials" ecosystem by leveraging Brain Family's experience in medical rehabilitation, educational consumption, and human-computer interaction [1] Group 2 - Sinovac Biotech's subsidiary completed the first subject enrollment for the Phase II clinical study of GB08 injection, a long-acting growth hormone for children with growth hormone deficiency [2] - The GB08 injection is the company's first independently developed Class I innovative drug [2] Group 3 - Heng Rui Medicine's subsidiary received approval for clinical trials of SHR-A2009, an antibody-drug conjugate targeting HER3, with no similar drugs approved globally [3] Group 4 - DiAo Microelectronics launched its self-developed high-performance eUSB repeater product, which supports bidirectional conversion between eUSB2 and USB2 signal schemes [4] - The product is designed for IoT, consumer electronics, and automotive electronics, enhancing the company's competitiveness in high-speed interface chips [4] Group 5 - Dongxin Co. announced the completion of its stock review and will resume trading on September 3 after a temporary suspension due to abnormal stock price fluctuations [5] - The company stated that its fundamentals and main business have not changed significantly [5] Group 6 - Junshi Biosciences received approval for clinical trials of JT118 injection, a "two-in-one" recombinant protein vaccine for monkeypox virus prevention, with no approved vaccines in the domestic market [6] Group 7 - Seres reported a 19.57% year-on-year increase in new energy vehicle sales in August, with production reaching 43,069 units and sales at 43,262 units [7][8] Group 8 - CATL has repurchased 8.69 million A-shares, totaling 2.131 billion yuan, with plans to continue the buyback based on market conditions [9] Group 9 - *ST Tianmao announced a cash option for shareholders during the period from September 15 to September 19, allowing them to exercise cash options at a price of 1.6 yuan per share [10]